HepQuant
HepQuant develops noninvasive, blood-based quantitative liver function diagnostics using oral cholate clearance methodology. Its FDA-approved HepQuant SHUNT test and HepQuant DuO Laboratory Developed Test serve hepatologists, gastroenterologists, and pharmaceutical companies running liver disease clinical trials.
- Company typePrivate
- Founded2007
- HeadquartersGreenwood Village, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What HepQuant does
HepQuant is a privately held clinical diagnostics company that develops noninvasive, blood-based quantitative tests for liver function assessment. Founded in 2007 by Dr. Gregory T. Everson (formerly Professor of Medicine and Director of Hepatology at the University of Colorado), the company is headquartered in Denver, Colorado with a CAP-accredited, CLIA-certified analytical laboratory at the Fitzsimons Innovation Community Campus in Aurora, adjacent to the University of Colorado Anschutz Medical Campus. Its core technology, the oral cholate challenge test (OCCT) combined with intravenous 13C-cholate clearance, directly measures hepatocyte function and portal blood inflow using LC-MS-based blood assays, producing a quantitative Disease Severity Index (DSI), SHUNT% (portal-systemic shunting), Hepatic Reserve, and a Risk for Adverse Clinical Events (RISK ACE) score.
HepQuant's commercial product portfolio comprises two principal offerings. The HepQuant SHUNT Liver Diagnostic Test received FDA premarket approval in June 2026 and is the only FDA-approved blood-based test for quantifying risk of large esophageal varices in adult patients with compensated cirrhosis (Child-Pugh Class A), demonstrated at 100% sensitivity and 100% negative predictive value in the SHUNT-V pivotal study (n=195). The HepQuant DuO is a Laboratory Developed Test (LDT) analyzed in-house, providing broader quantitative liver function and disease severity assessment, and is the primary product used in the company's Early Access Program for hepatologists and gastroenterologists. A Pharma Solutions module extends testing into clinical trial services, with named engagements including Madrigal Pharmaceuticals' Phase 3 MAESTRO-NAFLD-1 trial of resmetirom in MASH cirrhosis and Hepion Pharmaceuticals' Phase 2 ALTITUDE-NASH trial, plus a pilot with eGenesis on genetically modified porcine liver and research with the University of Pennsylvania on extracorporeal liver support.
HepQuant generates revenue primarily through two streams: (1) clinical diagnostic testing fees from healthcare providers ordering the HepQuant DuO and SHUNT tests (processed at its in-house lab), and (2) clinical trial testing services for pharmaceutical companies, with test costs flowing through standard laboratory billing and reimbursement. The company has historically funded operations through Colorado state grants (OEDIT Advanced Industry Accelerator Grant Program), University of Colorado research funding, and founder/backer capital (with President Randy Dietrich identified as a major financial backer since founding); no institutional venture capital rounds are disclosed. Commercial go-to-market relies on direct sales, a Chief Commercial Officer and regional Key Account Managers, and an event-driven presence at major hepatology conferences (AASLD, EASL, DDW, MASH-TAG).
HepQuant firmographics
Firmographics- Name
- HepQuant
- Legal name
- HepQuant, LLC
- Website
- https://hepquant.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- HepQuant develops noninvasive, blood-based quantitative liver function diagnostics using oral cholate clearance methodology. Its FDA-approved HepQuant SHUNT test and HepQuant DuO Laboratory Developed Test serve hepatologists, gastroenterologists, and pharmaceutical companies running liver disease clinical trials.
- Ownership category
- akta.pro rank
HepQuant industry classification
Industry- Product category
- Liver Disease Diagnostics
- NAICS
- Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Hepatology & Liver Disease (HLAKAEAB)
- akta.pro secondary industries
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Clinical Chemistry, Hematology & Coagulation Testing (Trial Support) (HLAGAEAE), Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)
Keywords
Where HepQuant is headquartered
LocationHeadquarters
- HQ city
- Greenwood Village
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
HepQuant business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Clinical Diagnostic Testing Services: HepQuant DuO is a Laboratory Developed Test (LDT) analyzed at the company's CAP-accredited, CLIA-certified laboratory. Healthcare providers submit patient samples for quantitative liver function assessment. Revenue is generated through test processing fees.
- Pharma Solutions / Clinical Trial Testing: Provides quantitative liver function testing services to pharmaceutical companies conducting clinical trials in liver disease. Includes support for Phase 2 and 3 drug trials, with HepQuant's tests used as endpoints for assessing treatment efficacy and patient stratification.
- Grant Funding: Received state-sponsored funding through Colorado Office of Economic Development and International Trade (OEDIT) Advanced Industry Accelerator Grant Program for supply chain development, regulatory advancements, and laboratory establishment.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Laboratory Developed Test - No public pricing available |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
HepQuant product offering
Product offeringCore offering
HepQuant develops and provides noninvasive, blood-based quantitative liver function tests analyzed at its own CAP-accredited, CLIA-certified laboratory. Its core offerings are the FDA PMA-approved HepQuant SHUNT test for identifying patients with compensated cirrhosis unlikely to have large esophageal varices, and the HepQuant DuO Laboratory Developed Test that delivers a Disease Severity Index (DSI) along with portal-systemic shunting and hepatic reserve metrics. The company also supplies quantitative liver endpoints to pharmaceutical sponsors for use in liver disease clinical trials.
Product overview
HepQuant offers a portfolio of noninvasive, blood-based, quantitative liver function tests. The core offerings are the FDA-approved HepQuant SHUNT® Liver Diagnostic Test and the HepQuant DuO® Laboratory Developed Test (LDT). The SHUNT test received FDA premarket approval in June 2026 for identifying patients unlikely to have large esophageal varices, while the HepQuant DuO test provides broader liver health assessment including Disease Severity Index (DSI), SHUNT%, Hepatic Reserve (HR%), and Risk for Adverse Clinical Events (RISK ACE) metrics. The Pharma Solutions module extends these tests for use in pharmaceutical clinical trials, enabling drug developers to assess liver function and physiology across various liver disease presentations.
Differentiator
Problem solved
Functional benefit
Brands
- HepQuant DuO: A noninvasive, blood-based quantitative test that measures liver function and portal circulation through a Disease Severity Index (DSI) score. It assesses critical liver cell processes and blood flow to the liver.
- HepQuant SHUNT
Products and services
- HepQuant SHUNT Liver Diagnostic Test FDA PMA-approved blood-based liver diagnostic test that generates a Disease Severity Index (DSI) score to identify adult patients with compensated cirrhosis (Child-Pugh Class A) unlikely to have large esophageal varices, potentially sparing them from endoscopy. It measures clearances of intravenously and orally administered cholate to assess liver function and portal-systemic shunting.
- HepQuant DuO
Quantifiable outcome
- 100% sensitivity and 100% negative predictive value for identifying patients unlikely to have large esophageal varices at DSI threshold of 18.3
- +4 more outcomes
Companies that use HepQuant
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
HepQuant technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
HepQuant partnerships and signals
Strategic signalScale indicators8 records
Recent moves7 records
Expansion highlights6 records
HepQuant competitors and assessment
Company assessmentBroad incumbents
- Labcorp: One of the largest US clinical reference laboratories operating CAP/CLIA labs nationwide with a broad hepatology and MASH testing menu. Relevant as both a potential commercial channel partner and a broad incumbent competing for clinical-trial central lab business against HepQuant's pharma services.
- Siemens Healthineers: Offers the ADVIA Centaur ELF (Enhanced Liver Fibrosis) test on its clinical chemistry immunoassay platforms, a widely deployed noninvasive liver fibrosis assessment. Comparable as an incumbent blood-based liver fibrosis diagnostic competing for hepatology adoption.
- Sonic Healthcare: Global clinical laboratory network with significant hepatology and gastroenterology testing services across the US, Europe, and Australia. Comparable as a broad incumbent that could partner with or compete against HepQuant for clinical-trial central lab and specialty liver testing volume.
- Bio-Techne: Life-science tools and diagnostics company with proprietary biomarker assay content (including exosome-based and proteomic platforms) sold into pharma clinical trials and research labs. Comparable as a broader biomarker and clinical-trial assay supplier overlapping with HepQuant's pharma-services positioning.
- Quest Diagnostics: Major US clinical reference laboratory with broad liver disease testing panels and clinical-trial central lab services. Comparable as a large incumbent serving hepatology providers and pharma sponsors across many of the same use cases HepQuant targets.
Direct peers
- Genfit: Developer of NIS4, a blood-based MASH diagnostic biomarker test commercialized in the US through Labcorp. Targets the same hepatology/MASH patient stratification use case and pharma clinical-trial endpoint positioning as HepQuant.
- Perspectum: Developer of LiverMultiScan, an MR-based quantitative liver diagnostic used for liver disease assessment and clinical-trial endpoints in MASH/NASH. Directly comparable to HepQuant as a quantitative, noninvasive liver diagnostic targeting hepatologists and pharma sponsors.
- Echosens: Commercial-stage developer of FibroScan, the dominant noninvasive point-of-care liver elastography device used by hepatologists worldwide. Directly competes with HepQuant for the same hepatology customer segment seeking noninvasive liver disease assessment.
Others
- Exact Sciences: Commercial-stage blood-based screening diagnostics company (Cologuard, Oncotype) with a large direct sales force targeting clinicians. Comparable as a US commercial-stage diagnostics platform whose playbook (CCO alumni at HepQuant helped build) and direct-to-physician model HepQuant is replicating for hepatology.
Emerging players
- C2N Diagnostics: Privately held blood-based diagnostics company with proprietary mass-spec-based assays and a CLIA-certified lab, known for the PrecivityAD Alzheimer's test. Comparable as an emerging specialty blood-based diagnostics company with a CAP/CLIA lab and pharma-services exposure, though focused on neurology rather than hepatology.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights6 records
Customer concentration
HepQuant social profiles
Digital presenceHepQuant compliance and trust
Trust signalCompliance4 records
HepQuant financial estimates
Financial estimateRevenue estimate
Valuation estimate
HepQuant leadership team
Management profileNumber of profiles
Profiles13 records
HepQuant funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HepQuant M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HepQuant
What does HepQuant do?
HepQuant develops and provides noninvasive, blood-based quantitative liver function tests analyzed at its own CAP-accredited, CLIA-certified laboratory. Its core offerings are the FDA PMA-approved HepQuant SHUNT test for identifying patients with compensated cirrhosis unlikely to have large esophageal varices, and the HepQuant DuO Laboratory Developed Test that delivers a Disease Severity Index (DSI) along with portal-systemic shunting and hepatic reserve metrics. The company also supplies quantitative liver endpoints to pharmaceutical sponsors for use in liver disease clinical trials.
Is HepQuant a public or private company?
HepQuant is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was HepQuant founded?
HepQuant was founded in 2007. It employs 11 to 50 people.
Where is HepQuant based?
HepQuant is headquartered in Greenwood Village, United States, in the North America region.
How does HepQuant make money?
Three revenue lines are on record. Clinical Diagnostic Testing Services are the primary driver. The others are pharma Solutions / Clinical Trial Testing and grant Funding.
Who are HepQuant's main competitors?
Broad incumbents on record are Labcorp, Siemens Healthineers, Sonic Healthcare, Bio-Techne and Quest Diagnostics. Direct peers are Genfit, Perspectum and Echosens. Exact Sciences is listed as an others. C2N Diagnostics is listed as an emerging player.
Does HepQuant have an API?
No public API is recorded for HepQuant.
What industry is HepQuant in?
HepQuant's product category is Liver Disease Diagnostics. Its primary akta.pro industry code is HLAKAEAB, Hepatology & Liver Disease, with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 621511 and its SIC code is 2835.